Istradefylline protects from cisplatin-induced ...
Type de document :
Compte-rendu et recension critique d'ouvrage
DOI :
PMID :
URL permanente :
Titre :
Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects
Auteur(s) :
Dewaeles, Edmone [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Carvalho, Kévin [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Fellah, Sandy [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Sim, Jaewon [Auteur]
Michigan State University [East Lansing]
Boukrout, Nihad [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Caillierez, Raphaelle [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Ramakrishnan, Hariharan [Auteur]
Michigan State University [East Lansing]
Van Der Hauwaert, Cynthia [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Vijaya Shankara, Jhenkruthi [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Martin, Nathalie [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Massri, Noura [Auteur]
Michigan State University [East Lansing]
Launay, Agathe [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Folger, Joseph [Auteur]
Michigan State University [East Lansing]
De Schutter, Clémentine [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Larrue, Romain [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Loison, Ingrid [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Goujon, Marine [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Jung, Matthieu [Auteur]
Institut de Génétique et de Biologie Moléculaire et Cellulaire [IGBMC]
Le Gras, Stéphanie [Auteur]
Institut de Génétique et de Biologie Moléculaire et Cellulaire [IGBMC]
Gomez-Murcia, Victoria [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Faivre, Emilie [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Lemaire, Julie [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Garat, Anne [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Beauval, Nicolas [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Maboudou, Patrice [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Gnemmi, Viviane [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Gibier, Jean-Baptiste [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Buee, Luc [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Abbadie, Corinne [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Glowacki, Francois [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Pottier, Nicolas [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Perrais, Michael [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cunha, Rodrigo [Auteur]
University of Coimbra [Portugal] [UC]
Annicotte, Jean-Sébastien [Auteur]
Metabolic functional (epi)genomics and molecular mechanisms involved in type 2 diabetes and related diseases - UMR 8199 - UMR 1283 [EGENODIA (GI3M)]
Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 [EGID]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Laumet, Geoffroy [Auteur]
Michigan State University [East Lansing]
Blum, David [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Cauffiez, Christelle [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Carvalho, Kévin [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Fellah, Sandy [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Sim, Jaewon [Auteur]
Michigan State University [East Lansing]
Boukrout, Nihad [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Caillierez, Raphaelle [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Ramakrishnan, Hariharan [Auteur]
Michigan State University [East Lansing]
Van Der Hauwaert, Cynthia [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Vijaya Shankara, Jhenkruthi [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Martin, Nathalie [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Massri, Noura [Auteur]
Michigan State University [East Lansing]
Launay, Agathe [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Folger, Joseph [Auteur]
Michigan State University [East Lansing]
De Schutter, Clémentine [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Larrue, Romain [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Loison, Ingrid [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Goujon, Marine [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Jung, Matthieu [Auteur]
Institut de Génétique et de Biologie Moléculaire et Cellulaire [IGBMC]
Le Gras, Stéphanie [Auteur]
Institut de Génétique et de Biologie Moléculaire et Cellulaire [IGBMC]
Gomez-Murcia, Victoria [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Faivre, Emilie [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Lemaire, Julie [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Garat, Anne [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Beauval, Nicolas [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Maboudou, Patrice [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Gnemmi, Viviane [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Gibier, Jean-Baptiste [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Buee, Luc [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Abbadie, Corinne [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Glowacki, Francois [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Pottier, Nicolas [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Perrais, Michael [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cunha, Rodrigo [Auteur]
University of Coimbra [Portugal] [UC]
Annicotte, Jean-Sébastien [Auteur]
Metabolic functional (epi)genomics and molecular mechanisms involved in type 2 diabetes and related diseases - UMR 8199 - UMR 1283 [EGENODIA (GI3M)]
Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 [EGID]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Laumet, Geoffroy [Auteur]
Michigan State University [East Lansing]
Blum, David [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Excellence Laboratory LabEx DISTALZ
Cauffiez, Christelle [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Titre de la revue :
The Journal of clinical investigation
Pagination :
e152924
Date de publication :
2022-11-15
ISSN :
1558-8238
Mot(s)-clé(s) en anglais :
G protein–coupled receptors
Nephrology
Pharmacology
Nephrology
Pharmacology
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologie
Résumé en anglais : [en]
Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity ...
Lire la suite >Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment.Lire moins >
Lire la suite >Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :
Date de dépôt :
2024-02-17T03:45:06Z
Fichiers
- document
- Accès libre
- Accéder au document
- TJClinInvestig2022_152924.pdf
- Accès libre
- Accéder au document